C-Path In Europe

Filter by Category

All Events Publications Webinars Workshops

December 12, 2023

C-Path Welcomes Mucopolysaccharidosis Clinical Trial Data Contribution from Children’s Hospital of Orange County into RDCA-DAP

TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare D

December 12, 2023

C-Path’s RDCA-DAP Program and PicnicHealth Announce Data Collaboration to Accelerate Rare Disease Research

TUCSON, Ariz., December 12, 2023 – Critical Path Institute (C-Path), a leader in advancing rare disease research, is pleased to

September 18, 2023

C-Path and EATRIS Join Forces with New Collaboration Agreement

AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastruct

July 19, 2023

The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development

TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therap

July 18, 2023

C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

AMSTERDAM and TUCSON, Ariz., July 18, 2023 — Critical Path Institute (C-Path) announced today the completion of the integration

June 7, 2023

Shaping the Global Innovation and Access Landscape for Better Paediatric Medicines: C-Path Becomes Official Partner of WHO

TUCSON, Ariz. and AMSTERDAM, June 7, 2023 — Critical Path Institute (C-Path), a leading global nonprofit committed to expediting

June 7, 2023

Newcastle University’s John Walton Muscular Dystrophy Research Centre Contributes Data to C-Path’s RDCA-DAP

TUCSON, Ariz., June 7, 2023 — Critical Path Institute (C-Path) announced today that Newcastle University UK’s John Walton Musc

April 26, 2023

C-Path Europe: A Global Vision of Success

TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies

January 25, 2023

C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform

TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss

November 2, 2022

C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial Data

TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collabora